Table 1.

Results of HGV Markers According to Treatment Stages in Cross-Sectional Study

Patients Undergoing Treatment (n = 74) Patients Having Completed Therapy (n = 32)
HGV-RNA positive 16/74 (21.6%)  3/32 (9.4%)  
Anti-E2 positive 1/74 (1.3%)  1/32 (3.1%) 
Patients Undergoing Treatment (n = 74) Patients Having Completed Therapy (n = 32)
HGV-RNA positive 16/74 (21.6%)  3/32 (9.4%)  
Anti-E2 positive 1/74 (1.3%)  1/32 (3.1%) 

Abbreviation: anti-E2, anti-E2 antibody.

Close Modal

or Create an Account

Close Modal
Close Modal